<DOC>
	<DOCNO>NCT00522457</DOCNO>
	<brief_summary>This study purpose demonstrate clinical efficacy investigational new drug ertumaxomab patient human epidermal growth factor receptor-2 ( HER-2/neu ) overexpressing ( 3+ 2+ positive Fluorescence In Situ Hybridization ( FISH ) test result ) metastatic breast cancer progress trastuzumab treatment . Ertumaxomab trifunctional bispecific antibody target Her-2/neu tumor cell CD3 T cell . Trifunctional antibody represent new concept target anticancer therapy . This new antibody class capability redirect T cell accessory immune effector cell ( e.g . macrophage , dendritic cell [ DCs ] natural killer [ NK ] cell ) tumor site . According preclinical data , trifunctional antibody activate immune cell , trigger complex anti-tumor immune response .</brief_summary>
	<brief_title>Phase II Study With Trifunctional Antibody Ertumaxomab Treat Metastatic Breast Cancer After Progression Trastuzumab Therapy</brief_title>
	<detailed_description>This study open-label , non-randomized , uncontrolled , two-stage phase II study evaluate efficacy safety ertumaxomab . Ertumaxomab administer three time 7 day interval constant rate 3 hour intravenous ( i.v . ) infusion accord follow dose schedule : 10 µg ( day 0 ) ; 100 µg ( day 7 ± 1 day ) 100 µg ( day 14 ± 1 day ) ( flat dos ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Key Women ≥ 18 year , Negative pregnancy test screen life expectancy least 3 month metastatic ( stage IV ) curable adenocarcinoma breast Measurable disease , define least one lesion measurable one dimension ( RECIST ) HER2 overexpression 3+ 2+ FISH positive Patients must receive one prior therapy trastuzumab last treatment entry study . If trastuzumab give single agent treatment , patient must receive prior chemotherapy metastatic disease Trastuzumab discontinue study entry disease progress trastuzumab therapy Eastern Cooperative Oncology Group ( ECOG ) performance score ≤ 2 Adequate hematological , liver kidney function Key Women pregnant breast feed Any history symptom indicative brain central nervous system metastases Prior diagnosis malignancy cure surgery alone less 5 year study entry ( except situ carcinoma cervix adequately treat basal cell carcinoma skin ) Human antimurine antibody positive hypersensitivity murine proteins component study drug Known autoimmune disease , Human immunodeficiency virus ( HIV ) , hepatitis B C infection well acute chronic infection concurrent nonmalignant comorbidities uncontrolled Any concurrent chemotherapy , hormonal therapy , immunotherapy corticoid therapy Concurrent antibiotic treatment Any concurrent investigational treatment metastatic disease Cardiovascular exclusion criterion : Unstable uncontrolled pectorial angina Myocardial infarction last 6 month Valvular heart disease require treatment Cardiomyopathy ( congestive , hypertrophic restrictive ) Acute myocarditis Congestive heart failure ( CHF ) : dyspnea , clinically radiologically diagnose Left ventricular ejection fraction ( LVEF ) outside institution 's normal range base echocardiography rest Left ventricular diameter &gt; 56 mm base Mmode echocardiography rest Arrhythmias require treatment ( atrioventricular block II/III degree , atrial fibrillation , ventricular tachycardia ) Poorly uncontrolled hypertension , asthma , seizure , allergy , pulmonary dysfunction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>investigational drug</keyword>
	<keyword>drug therapy</keyword>
	<keyword>Antineoplastic Protocols</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Stage IV breast cancer</keyword>
	<keyword>Her-2/neu express breast cancer</keyword>
	<keyword>Her-2/neu</keyword>
	<keyword>Trastuzumab refractory</keyword>
</DOC>